ECE2020 Audio ePoster Presentations Diabetes, Obesity, Metabolism and Nutrition (285 abstracts)
1Centre of Postgraduate Medical Education, Department of Neuroendocrinology, Warsaw, Poland; 2Centre of Postgraduate Medical Education, Department of Dermatology, Warsaw, Poland; 3Centre of Postgraduate Medical Education, Department of Endocrinology, Warsaw, Poland
Adipokines belong to a group of proteins involved in the pathogenesis and progression of immune/inflammatory diseases. It is an open question whether and how adipokines contribute to these diseases. Adiponectin might be a key regulator of the immune system, playing a role in the progression of inflammatory disorders. Omentin has been recognized as an anti-inflammatory adipokine with influence on immune response regulation and inflammation, Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by vasculopathy and fibrosis of the skin and internal organs. The studies showed a possible role of adipokines in the development of fibrosis and modulation of the immune response in the course of SSc. We aimed to evaluate plasma levels of adiponectin and omentin-1 in SSc patients in basal conditions as well as in prospective observations.
Material and Methods: 59 patients with SSc and 27 healthy controls, matched with age, BMI and HOMA-IR, were enrolled in the study. The severity of the skin fibrosis in SSc individuals was evaluated using the Rodnan scale. In all participants, fasting plasma adiponectin and omentin-1 concentrations were assessed using the ELISA.
Results: Omentin-1 levels were significantly higher in patients with SSc compared with the controls. These differences remained marked after adjustment to BMI. No changes were seen between omentin-1 concentrations in prospective analyses in SSc patients (0, 6 months, 9 months). Although adiponectin had a trend to lower values in SSc individuals in comparison to the controls, the differences were not significant. However, after adjustment to BMI, these differences became significant. Similar to omentin-1, there were no adiponectin fluctuations in the follow-up. Amongst two selected adipokines, only adiponectin levels correlated with the Rodnan scale (R = −0.21, P < 0.05). To conclude, adiponectin and omentin-1 cannot be regarded as potential metabolic markers of a course of systemic sclerosis. However, higher omentin-1 and lower adiponectin concentrations after adjustment to BMI, as seen in SSc patients, may indicate an influence of these adipokines on pathomechanisms involved in systemic sclerosis.
SSc | Control | P | P (after adjustment to BMI) | |
Adiponectin (ug/ml) | 8.47 ± 4.06 | 10.6 ± 5.4 | ns | < 0.05 |
Omentin-1 (ng/ml) | 604 ± 93 | 506 ± 138 | < 0.05 | < 0.05 |
0 | 6 months | 9 months | p | |
Adiponectin (mg/ml) | 8.47 ± 4.06 | 8.72 ± 3.85 | 8.04 ± 3.81 | ns |
Omentin-1 (ng/ml) | 604 ± 193 | 619 ± 257 | 601 ± 238 | ns |
This study was supported by the CMKP grant 506-1-31-22-19.